27918-19-0

Basic information

• Product Name: 4-Sulfonamide-phenylhydrazine hydrochloride
• Synonyms: P-SULFONAMIDOPHENYL HYDRAZINE HYDROCHLORIDE;Phenylhydrazine-4-sulfonamide hydrochloride;4-HYDRAZINO BENZENE SULFONAMIDE HCL;4-HYDRAZINOBENZENESULFONAMIDE HYDROCHLORIDE;4-HYDRAZINOBENZENESULPHONAMIDE HYDROCHLORIDE;4-SULPHANAMIDE PHENYL HYDRAZINE HYDROCHLORIDE;4-SULPHONAMIDOPHENYL HYDRAZINE HCL;4-SULPHONAMIDOPHENYLHYDRAZINE HYDROCHLORIDE
• CAS NO: 27918-19-0
• Molecular Formula: C₆H₉N₃O₂S*ClH
• Molecular Weight: 223.68
• Product Categories: Phenylhydrazine;API intermediates;Osteoarthritis and Rheumatoid Arthritis;Celecoxib
• Mol File: 27918-19-0.mol
• Article Data: 15

Chemical Properties

• Melting Point: 180 °C
• Appearance: /
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), Water (Slightly)
• CAS DataBase Reference: 4-Sulfonamide-phenylhydrazine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Sulfonamide-phenylhydrazine hydrochloride(27918-19-0)
• EPA Substance Registry System: 4-Sulfonamide-phenylhydrazine hydrochloride(27918-19-0)

Safety Data

• Safety Statements: S24/25:
• Hazardous Substances Data: 27918-19-0(Hazardous Substances Data)

Usage

General Description

4-Sulfonamide-Phenylhydrazine Hydrochloride is a chemical compound that is commonly used as a reagent in organic synthesis. It is a derivative of phenylhydrazine, which is used in various chemical reactions and is known for its sulfonamide group. The hydrochloride salt form of this compound is often used for its stability and solubility in aqueous solutions. 4-Sulfonamide-Phenylhydrazine Hydrochloride has been used in the development of pharmaceuticals and as a reagent in the preparation of various organic compounds. It is important to handle this chemical with caution and follow proper safety protocols when working with it.

InChI:InChI=1/C6H8N3O2S.ClH/c7-8-5-1-3-6(4-2-5)9-12(10)11;/h1-4,8H,7H2,(H,9,10,11);1H

Upstream product

• 35282-78-1 4-(aminosulphonyl)benzenediazonium chloride 
• 63-74-1 sulfanilamide 

Downstream Products

• 111607-53-5 4-{N'-[(E)-1-Phenyl-3-p-tolyl-prop-2-en-(E)-ylidene]-hydrazino}-benzenesulfonamide 
• 122259-16-9 4-{N'-[(E)-3-(4-Methoxy-phenyl)-1-phenyl-prop-2-en-(E)-ylidene]-hydrazino}-benzenesulfonamide 
• 71203-35-5 4-[4,5-dihydro-5-(4-methoxyphenyl)-3-phenyl-1H-pyrazol-1-yl]benzenesulfonamide 
• 162130-64-5 4-[3-(4-Nitro-phenyl)-3,3a,4,5-tetrahydro-benzo[g]indazol-2-yl]-benzenesulfonamide 
• 178975-20-7 4-[1,4-dihydro-3-(trifluoromethyl)-[1]benzothiopyrano[4,3-c]pyrazol-1-yl]benzenesulfonamide 
• 188817-14-3 4-[5-(2-Nitro-phenyl)-3-trifluoromethyl-pyrazol-1-yl]-benzenesulfonamide 
• 845674-84-2 4-(5-(4-iodophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide 
• 111607-61-5 4-(3-phenyl-5-p-tolyl-1H-pyrazol-1-yl)benzenesulfonamide 

Relevant articles and documents

Synthetic method of celecoxib intermediate P-hydrazinamide hydrochloride

The method, comprises the following steps :1): preparing a sulfanilamide hydrochloric acid aqueous solution, to prepare a sodium nitrite solution ;2) to acidify, and then acidifying the resulting reaction solution to 1 with ;3) powder, activated carbon to

Pyrazole–coumarin and pyrazole–quinoline chalcones as potential antitubercular agents

Pyrazole, coumarin, and quinoline are medicinally important moieties. In this study, two series of novel pyrazole–coumarin chalcones and pyrazole–quinoline chalcones were synthesized using multiple-step reactions. All the synthesized compounds were well c

An Integrated Continuous Flow Micro-Total Ultrafast Process System (μ-TUFPS) for the Synthesis of Celecoxib and Other Cyclooxygenase Inhibitors

Integrated continuous manufacturing has emerged as a promising device for the rapid manufacturing of active pharmaceutical ingredients (APIs). We herein report a newly designed continuous flow micro-total process system platform for the rapid manufacturing of celecoxib, a selective nonsteroidal anti-inflammatory drug. This approach has been proven generally for the synthesis of several alkyl and aryl substituted pyrazoles. In order to minimize the tedious work-up process of potential reaction intermediates/products, we have developed a continuous flow extraction and separation platform to carry out the entire reaction sequence resulting in a short residence time with good yield. The present process was further extended to gram-scale synthesis of the COX-2-related API, viz. celecoxib, in the continuous flow process.